Loading...

Davide Verotta, PhD

TitleProfessor
SchoolUCSF School of Pharmacy
DepartmentClinical Pharmacy
Address513 Parnassus Avenue
San Francisco CA 94117
Phone415-476-1556
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    School of Pharmacy, UCSF2005Dean's Recognition for Excellence in Teaching

    Collapse Overview 
    Collapse Overview
    Dr. Davide Verotta’s main research interests are in pharmacokinetics and pharmacodynamics (PKPD) and mathematical statistical (MS) modeling. In PKPD, his main areas of interest are: mechanistic modeling (where prior knowledge about parts of a PKPD system is embedded in the model describing it); the development of empirical models (where no prior knowledge is embedded in the model) to analyze, simulate and control; population PKPD modeling with particular regard to empirical methods for population data analysis. In MS modeling, his main interests are in linear and non-linear system analysis, control, and experimental design. He is involved in collaborative research with scientists and different investigators in PKPD and clinical therapy (notably HIV therapy) modeling. Additional areas of investigation are the use of Bayesian methods, in particular applied to pharmacogenomics and mechanistic modeling, fractional differential equations, and applications of functional data analysis to population PKPD.


    Collapse Research 
    Collapse Research Activities and Funding
    Modeling Complex Pharmacokinetics and Pharmacodynamics
    NIH/NIAID R01AI050587Sep 30, 2002 - May 31, 2013
    Role: Principal Investigator
    MODELS FOR BIOLOGICAL DATA RELEVANT TO HEALTH CARE
    NIH/NIGMS R29GM051197Sep 1, 1995 - Aug 31, 2001
    Role: Principal Investigator
    Pharmacokinetic / Pharmacodynamic Data Analysis
    NIH/NIGMS R01GM026676Sep 1, 1979 - Aug 31, 2012
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Haagensen JA, Verotta D, Huang L, Spormann A, Yang K. New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms. Antimicrob Agents Chemother. 2015 Jul; 59(7):4074-81. PMID: 25918138; PMCID: PMC4468651.
    2. Huang L, Haagensen J, Verotta D, Lizak P, Aweeka F, Yang K. Determination of meropenem in bacterial media by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 15; 961:71-6. PMID: 24861874; PMCID: PMC4104812.
    3. Frymoyer A, Lee S, Bonifacio SL, Meng L, Lucas SS, Guglielmo BJ, Sun Y, Verotta D. Every 36-h gentamicin dosing in neonates with hypoxic-ischemic encephalopathy receiving hypothermia. J Perinatol. 2013 Oct; 33(10):778-82. PMID: 23702622; PMCID: PMC3762884.
    4. Frymoyer A, Meng L, Bonifacio SL, Verotta D, Guglielmo BJ. Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia. Pharmacotherapy. 2013 Jul; 33(7):718-26. PMID: 23553582; PMCID: PMC3700641.
    5. Frymoyer A, Verotta D, Jacobson P, Long-Boyle J. Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol. 2013 Feb; 75(2):463-75. PMID: 22765258; PMCID: PMC3579261.
    6. Dong BJ, Zheng Y, Hughes MD, Frymoyer A, Verotta D, Lizak P, Sawe F, Currier JS, Lockman S, Aweeka FT. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS. 2012 Apr 24; 26(7):833-41. PMID: 22301417; PMCID: PMC3506024.
    7. Li L, Galloway GP, Verotta D, Everhart ET, Baggott MJ, Coyle JR, Lopez JC, Mendelson J. A method to quantify illicit intake of drugs from urine: methamphetamine. J Pharmacol Exp Ther. 2011 Jul; 338(1):31-6. PMID: 21450932; PMCID: PMC3126645.
    8. Verotta D. Fractional dynamics pharmacokinetics-pharmacodynamic models. J Pharmacokinet Pharmacodyn. 2010 Jun; 37(3):257-76. PMID: 20455076; PMCID: PMC2889283.
    9. Verotta D. Fractional compartmental models and multi-term Mittag-Leffler response functions. J Pharmacokinet Pharmacodyn. 2010 Apr; 37(2):209-15; discussion 217-20. PMID: 20405313; PMCID: PMC2861176.
    10. Schwartz JB, Verotta D. Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Clin Pharmacol Ther. 2009 Nov; 86(5):497-502. PMID: 19571802.
      View in: PubMed
    11. Perger L, Rentsch KM, Kullak-Ublick GA, Verotta D, Fattinger K. Oral heroin in opioid-dependent patients: pharmacokinetic comparison of immediate and extended release tablets. Eur J Pharm Sci. 2009 Mar 02; 36(4-5):421-32. PMID: 19084595; PMCID: PMC2753514.
    12. Kshirsagar S, Gear R, Levine J, Verotta D. A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain. J Pharmacokinet Pharmacodyn. 2008 Feb; 35(1):69-83. PMID: 17943420.
      View in: PubMed
    13. Kang D, Verotta D. Reversible jump Markov chain Monte Carlo for deconvolution. J Pharmacokinet Pharmacodyn. 2007 Jun; 34(3):263-87. PMID: 17221310.
      View in: PubMed
    14. Kshirsagar SA, Blaschke TF, Sheiner LB, Krygowski M, Acosta EP, Verotta D. Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria. J Pharmacokinet Pharmacodyn. 2007 Feb; 34(1):35-55. PMID: 17004125.
      View in: PubMed
    15. Labbé L, Verotta D. A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients. J Pharmacokinet Pharmacodyn. 2006 Aug; 33(4):519-42. PMID: 16786410.
      View in: PubMed
    16. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn. 2006 Jun; 33(3):227-79. PMID: 16404503.
      View in: PubMed
    17. Kang D, Verotta D, Schwartz JB. Population analyses of amlodipine in patients living in the community and patients living in nursing homes. Clin Pharmacol Ther. 2006 Jan; 79(1):114-24. PMID: 16413246.
      View in: PubMed
    18. Kang D, Schwartz JB, Verotta D. Sample size computations for PK/PD population models. J Pharmacokinet Pharmacodyn. 2005 Dec; 32(5-6):685-701. PMID: 16284914.
      View in: PubMed
    19. Csajka C, Drover D, Verotta D. The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption. Pharm Res. 2005 Aug; 22(8):1227-35. PMID: 16078132.
      View in: PubMed
    20. Csajka C, Haller CA, Benowitz NL, Verotta D. Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. Br J Clin Pharmacol. 2005 Mar; 59(3):335-45. PMID: 15752380; PMCID: PMC1884794.
    21. Valle M, Di Salle E, Jannuzzo MG, Poggesi I, Rocchetti M, Spinelli R, Verotta D. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. Br J Clin Pharmacol. 2005 Mar; 59(3):355-64. PMID: 15752382; PMCID: PMC1884784.
    22. Csajka C, Imbimbo BP, Piccinno A, Dostert P, Verotta D. Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. J Pharmacol Exp Ther. 2005 May; 313(2):647-57. PMID: 15671203.
      View in: PubMed
    23. Kang D, Schwartz JB, Verotta D. A sample size computation method for non-linear mixed effects models with applications to pharmacokinetics models. Stat Med. 2004 Aug 30; 23(16):2551-66. PMID: 15287084.
      View in: PubMed
    24. Valle M, Price RW, Nilsson A, Heyes M, Verotta D. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain. 2004 May; 127(Pt 5):1047-60. PMID: 15013955.
      View in: PubMed
    25. Verotta D. Volterra series in pharmacokinetics and pharmacodynamics. J Pharmacokinet Pharmacodyn. 2003 Oct; 30(5):337-62. PMID: 14977164.
      View in: PubMed
    26. Kang D, Verotta D, Krecic-Shepard ME, Modi NB, Gupta SK, Schwartz JB. Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. Clin Pharmacol Ther. 2003 Jan; 73(1):31-40. PMID: 12545141.
      View in: PubMed
    27. Drover DR, Angst MS, Valle M, Ramaswamy B, Naidu S, Stanski DR, Verotta D. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology. 2002 Oct; 97(4):827-36. PMID: 12357147.
      View in: PubMed
    28. Pitsiu M, Gries JM, Benowitz N, Gourlay SG, Verotta D. Modeling nicotine arterial-venous differences to predict arterial concentrations and input based on venous measurements: application to smokeless tobacco and nicotine gum. J Pharmacokinet Pharmacodyn. 2002 Aug; 29(4):383-402. PMID: 12518710.
      View in: PubMed
    29. Verotta D, Schaedeli F. Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials. Math Biosci. 2002 Apr; 176(2):163-83. PMID: 11916507.
      View in: PubMed
    30. Schaedeli F, Pitsiu M, Benowitz NL, Gourlay SG, Verotta D. Influence of arterial vs. venous sampling site on nicotine tolerance model selection and parameter estimation. J Pharmacokinet Pharmacodyn. 2002 Feb; 29(1):49-66. PMID: 12194535.
      View in: PubMed
    31. Lu J, Gries JM, Verotta D, Sheiner LB. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance. J Pharmacokinet Pharmacodyn. 2001 Aug; 28(4):343-62. PMID: 11677931.
      View in: PubMed
    32. Pitsiu M, Sathyan G, Gupta S, Verotta D. A semiparametric deconvolution model to establish in vivo-in vitro correlation applied to OROS oxybutynin. J Pharm Sci. 2001 Jun; 90(6):702-12. PMID: 11357173.
      View in: PubMed
    33. Gries JM, Verotta D. Linear mixed-effect multivariate adaptive regression splines applied to nonlinear pharmacokinetics data. J Biopharm Stat. 2000 Aug; 10(3):383-98. PMID: 10959918.
      View in: PubMed
    34. Fattinger K, Benowitz NL, Jones RT, Verotta D. Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine. Eur J Clin Pharmacol. 2000 Jul; 56(4):305-10. PMID: 10954344.
      View in: PubMed
    35. Kindler CH, Verotta D, Gray AT, Gropper MA, Yost CS. Additive inhibition of nicotinic acetylcholine receptors by corticosteroids and the neuromuscular blocking drug vecuronium. Anesthesiology. 2000 Mar; 92(3):821-32. PMID: 10719961.
      View in: PubMed
    36. Gries JM, Munafo A, Porchet HC, Verotta D. Down-regulation models and modeling of testosterone production induced by recombinant human choriogonadotropin. J Pharmacol Exp Ther. 1999 Apr; 289(1):371-7. PMID: 10087026.
      View in: PubMed
    37. Verotta D. A general solution for nonparametric control of a linear system using computer-controlled infusion pumps. IEEE Trans Biomed Eng. 1999 Jan; 46(1):44-50. PMID: 9919825.
      View in: PubMed
    38. Verotta D. Characterizing the variability of system kernel and input estimates. Ann Biomed Eng. 1998 Sep-Oct; 26(5):870-82. PMID: 9779960.
      View in: PubMed
    39. Park K, Verotta D, Gupta SK, Sheiner LB. Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile. J Pharmacokinet Biopharm. 1998 Aug; 26(4):471-92. PMID: 10214563.
      View in: PubMed
    40. Gries JM, Benowitz N, Verotta D. Importance of chronopharmacokinetics in design and evaluation of transdermal drug delivery systems. J Pharmacol Exp Ther. 1998 May; 285(2):457-63. PMID: 9580583.
      View in: PubMed
    41. Park K, Verotta D, Gupta SK, Sheiner LB. Passive versus electrotransport-facilitated transdermal absorption of ketorolac. Clin Pharmacol Ther. 1998 Mar; 63(3):303-15. PMID: 9542474.
      View in: PubMed
    42. Vanhove GF, Gries JM, Verotta D, Sheiner LB, Coombs R, Collier AC, Blaschke TF. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997 Nov; 41(11):2433-8. PMID: 9371346; PMCID: PMC164141.
    43. Vanhove GF, Kastrissios H, Gries JM, Verotta D, Park K, Collier AC, Squires K, Sheiner LB, Blaschke TF. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997 Nov; 41(11):2428-32. PMID: 9371345; PMCID: PMC164140.
    44. Stanley G, Verotta D, Craft N, Siegel RA, Schwartz JB. Age effects on interrelationships between lung volume and heart rate during standing. Am J Physiol. 1997 Nov; 273(5 Pt 2):H2128-34. PMID: 9374744.
      View in: PubMed
    45. Park K, Verotta D, Blaschke TF, Sheiner LB. A semiparametric method for describing noisy population pharmacokinetic data. J Pharmacokinet Biopharm. 1997 Oct; 25(5):615-42. PMID: 9679225.
      View in: PubMed
    46. Fattinger K, Verotta D, Benowitz NL. Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans. J Pharmacol Exp Ther. 1997 Jun; 281(3):1238-46. PMID: 9190859.
      View in: PubMed
    47. Gries JM, Troconiz IF, Verotta D, Jacobson M, Sheiner LB. A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex. Clin Pharmacol Ther. 1997 Jan; 61(1):70-82. PMID: 9024175.
      View in: PubMed
    48. Verotta D. A general framework for non-parametric subject-specific and population deconvolution methods for in vivo-in vitro correlation. Adv Exp Med Biol. 1997; 423:43-52. PMID: 9269482.
      View in: PubMed
    49. Fattinger KE, Verotta D, Porchet HC, Munafo A, Le Cotonnec JY, Sheiner LB. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. Am J Physiol. 1996 Oct; 271(4 Pt 1):E775-87. PMID: 8897868.
      View in: PubMed
    50. Gries JM, Benowitz N, Verotta D. Chronopharmacokinetics of nicotine. Clin Pharmacol Ther. 1996 Oct; 60(4):385-95. PMID: 8873686.
      View in: PubMed
    51. Stanley G, Verotta D, Craft N, Siegel RA, Schwartz JB. Age and autonomic effects on interrelationships between lung volume and heart rate. Am J Physiol. 1996 May; 270(5 Pt 2):H1833-40. PMID: 8928893.
      View in: PubMed
    52. Gries JM, Upton R, Huang YF, Verotta D. A descriptive tool to characterize nonlinear kinetics, with applications to meperidine and lidocaine. J Pharm Sci. 1996 Apr; 85(4):362-8. PMID: 8901069.
      View in: PubMed
    53. Verotta D. Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems. Crit Rev Biomed Eng. 1996; 24(2-3):73-139. PMID: 9108983.
      View in: PubMed
    54. Fattinger KE, Verotta D. A nonparametric subject-specific population method for deconvolution: II. External validation. J Pharmacokinet Biopharm. 1995 Dec; 23(6):611-34. PMID: 8733949.
      View in: PubMed
    55. Fattinger KE, Sheiner LB, Verotta D. A new method to explore the distribution of interindividual random effects in non-linear mixed effects models. Biometrics. 1995 Dec; 51(4):1236-51. PMID: 8589220.
      View in: PubMed
    56. Fattinger KE, Verotta D. A nonparametric subject-specific population method for deconvolution: I. Description, internal validation, and real data examples. J Pharmacokinet Biopharm. 1995 Dec; 23(6):581-610. PMID: 8733948.
      View in: PubMed
    57. Fattinger KE, Verotta D. Estimating bioavailability when clearance changes in time: the effect of model misspecification. Clin Pharmacol Ther. 1995 Nov; 58(5):595-600. PMID: 7586955.
      View in: PubMed
    58. Sheiner LB, Verotta D. Further notes on physiologic indirect response models. Clin Pharmacol Ther. 1995 Aug; 58(2):238-40. PMID: 7648775.
      View in: PubMed
    59. Verotta D, Sheiner LB. A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data. J Pharmacokinet Biopharm. 1995 Feb; 23(1):1-4. PMID: 8576839.
      View in: PubMed
    60. Gumbleton M, Oie S, Verotta D. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences. Br J Clin Pharmacol. 1994 Nov; 38(5):389-400. PMID: 7893578; PMCID: PMC1364870.
    61. Troconiz IF, Sheiner LB, Verotta D. Semiparametric models for antagonistic drug interactions. J Appl Physiol (1985). 1994 May; 76(5):2224-33. PMID: 7914889.
      View in: PubMed
    62. Verotta D. Estimation and model selection in constrained deconvolution. Ann Biomed Eng. 1993 Nov-Dec; 21(6):605-20. PMID: 8116913.
      View in: PubMed
    63. Verotta D. Two constrained deconvolution methods using spline functions. J Pharmacokinet Biopharm. 1993 Oct; 21(5):609-36. PMID: 8145134.
      View in: PubMed
    64. Schwartz JB, Troconiz IF, Verotta D, Liu S, Capili H. Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil. J Pharmacol Exp Ther. 1993 May; 265(2):690-8. PMID: 8496816.
      View in: PubMed
    65. Cahalan MK, Hashimoto Y, Aizawa K, Verotta D, Ionescu P, Balea M, Eger EI, Benet LZ, Ehrenfeld WK, Goldstone J. Elderly, conscious patients have an accentuated hypotensive response to nitroglycerin. Anesthesiology. 1992 Oct; 77(4):646-55. PMID: 1416161.
      View in: PubMed
    66. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992 Oct; 20(5):511-28. PMID: 1287200.
      View in: PubMed
    67. Verotta D, Sheiner LB. Comparing responses when each response is a curve. Am J Physiol. 1992 Jul; 263(1 Pt 2):R206-14. PMID: 1636790.
      View in: PubMed
    68. Carrington PA, Hill RJ, Levin J, Verotta D. Effects of interleukin 3 and interleukin 6 on platelet recovery in mice treated with 5-fluorouracil. Exp Hematol. 1992 May; 20(4):462-9. PMID: 1568463.
      View in: PubMed
    69. Verotta D, Sheiner LB. Semiparametric analysis of non-steady-state pharmacodynamic data. J Pharmacokinet Biopharm. 1991 Dec; 19(6):691-712. PMID: 1815048.
      View in: PubMed
    70. Verotta D, Kitts J, Rodriguez R, Coldwell J, Miller RD, Sheiner LB. Reversal of neuromuscular blockade in humans by neostigmine and edrophonium: a mathematical model. J Pharmacokinet Biopharm. 1991 Dec; 19(6):713-29. PMID: 1687690.
      View in: PubMed
    71. Verotta D, Sheiner LB, Beal SL. Mean time parameters for generalized physiological flow models (semihomogeneous linear systems). J Pharmacokinet Biopharm. 1991 Jun; 19(3):319-31. PMID: 1875285.
      View in: PubMed
    72. Verotta D. An application of the D-optimal criterion to define the experimental design for a particular class of semi-parametric models. Comput Methods Programs Biomed. 1990 Nov; 33(3):181-7. PMID: 2279391.
      View in: PubMed
    73. Verotta D. Comments on two recent deconvolution methods. J Pharmacokinet Biopharm. 1990 Oct; 18(5):483-9; discussion 489-99. PMID: 2266499.
      View in: PubMed
    74. Björkman S, Stanski DR, Verotta D, Harashima H. Comparative tissue concentration profiles of fentanyl and alfentanil in humans predicted from tissue/blood partition data obtained in rats. Anesthesiology. 1990 May; 72(5):865-73. PMID: 2339802.
      View in: PubMed
    75. Schwartz JB, Verotta D, Sheiner LB. Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions. J Pharmacol Exp Ther. 1989 Dec; 251(3):1032-8. PMID: 2600802.
      View in: PubMed
    76. Boyd RA, Chin SK, Don-Pedro O, Verotta D, Sheiner LB, Williams RL, Giacomini KM. The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin Pharmacol Ther. 1989 Oct; 46(4):408-19. PMID: 2791444.
      View in: PubMed
    77. Verotta D, Sheiner LB, Ebling WF, Stanski DR. A semiparametric approach to physiological flow models. J Pharmacokinet Biopharm. 1989 Aug; 17(4):463-91. PMID: 2614682.
      View in: PubMed
    78. Bortolotti A, Castelli D, Verotta D, Bonati M. Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. Eur J Drug Metab Pharmacokinet. 1989 Apr-Jun; 14(2):145-51. PMID: 2591419.
      View in: PubMed
    79. Verotta D. An inequality-constrained least-squares deconvolution method. J Pharmacokinet Biopharm. 1989 Apr; 17(2):269-89. PMID: 2677315.
      View in: PubMed
    80. Verotta D, Beal SL, Sheiner LB. Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am J Physiol. 1989 Apr; 256(4 Pt 2):R1005-10. PMID: 2705568.
      View in: PubMed
    81. Imbimbo BP, Imbimbo E, Daniotti S, Verotta D, Bassotti G. A new criterion for selection of pharmacokinetic multiexponential equations. J Pharm Sci. 1988 Sep; 77(9):784-9. PMID: 2976092.
      View in: PubMed
    82. Verotta D. Software for experimental design: the computer program EXCAD. Comput Methods Programs Biomed. 1988 Mar-Apr; 26(2):159-66. PMID: 3359766.
      View in: PubMed
    83. Verotta D, Petrillo P, La Regina A, Rocchetti M, Tavani A. D-optimal design applied to binding saturation curves of an enkephalin analog in rat brain. Life Sci. 1988; 42(6):735-43. PMID: 2828802.
      View in: PubMed
    84. Verotta D, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm. Comput Appl Biosci. 1987 Nov; 3(4):345-9. PMID: 2898970.
      View in: PubMed
    85. Schüttler J, Stanski DR, White PF, Trevor AJ, Horai Y, Verotta D, Sheiner LB. Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man. J Pharmacokinet Biopharm. 1987 Jun; 15(3):241-53. PMID: 3668802.
      View in: PubMed
    86. Petrillo P, Tavani A, Verotta D, Robson LE, Kosterlitz HW. Differential postnatal development of mu-, delta- and kappa-opioid binding sites in rat brain. Brain Res. 1987 Jan; 428(1):53-8. PMID: 3815117.
      View in: PubMed
    87. Verotta D, Recchia M, Urso R. MODDIS: a microcomputer program for model discrimination. Comput Methods Programs Biomed. 1986 Apr; 22(2):209-18. PMID: 3635460.
      View in: PubMed
    88. Gobbi M, Barone D, Dagnino G, Verotta D, Mennini T. Allosteric inhibition as a model to explain flatter displacement curves in binding experiments: application to "heterogeneous" serotonin receptors. J Recept Res. 1986; 6(1):27-46. PMID: 3712356.
      View in: PubMed
    89. Bartosek I, Verotta D. Non-linear fitting program for biological data. Int J Biomed Comput. 1986 Jan; 18(1):25-8. PMID: 3753954.
      View in: PubMed
    Davide's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP